Anthera Pharmaceuticals Inc. (NASDAQ:ANTH)’s share price fell 1.9% during mid-day trading on Tuesday . The company traded as low as $3.12 and last traded at $3.13, with a volume of 442,932 shares traded. The stock had previously closed at $3.19.

A number of brokerages recently issued reports on ANTH. Zacks Investment Research lowered Anthera Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 12th. Jefferies Group restated a “buy” rating on shares of Anthera Pharmaceuticals in a research note on Thursday, June 9th. FBR & Co restated a “hold” rating on shares of Anthera Pharmaceuticals in a research note on Monday, June 20th. Finally, HC Wainwright began coverage on Anthera Pharmaceuticals in a research note on Friday, July 8th. They issued a “buy” rating and a $10.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $9.58.

The company’s market capitalization is $125.94 million. The firm’s 50-day moving average price is $3.21 and its 200-day moving average price is $3.42.

Anthera Pharmaceuticals (NASDAQ:ANTH) last issued its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by $0.04. Equities research analysts expect that Anthera Pharmaceuticals Inc. will post ($1.37) earnings per share for the current fiscal year.

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.